Skip to main content
Jinyu Bio-Technology Co.,Ltd. logo

Jinyu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 600201 ISIN · CNE000000Y37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,776 across all filing types
Latest filing 2021-11-10 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600201

About Jinyu Bio-Technology Co.,Ltd.

http://jinyubiotech.com/

Jinyu Bio-Technology Co., Ltd. focuses on the research, development, and manufacturing of veterinary biological products and pharmaceuticals. The company is a prominent supplier of animal vaccines, particularly specializing in Foot-and-Mouth Disease (FMD) vaccines, brucellosis vaccines, and solutions for swine and poultry diseases. It utilizes advanced biotechnology platforms, including large-scale suspension culture and high-efficiency purification processes, to produce high-titer, high-purity biologicals. The organization operates sophisticated research facilities and Biosafety Level 3 (P3) laboratories to support the development of diagnostic reagents and preventive treatments. Its operations center on enhancing animal health through scientific innovation, providing comprehensive disease control strategies for the global livestock industry and large-scale agricultural operations.

Recent filings

Filing Released Lang Actions
金宇生物技术股份有限公司第十届董事会第十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of the company 金宇生物技术股份有限公司. It details the approval of specific agenda items related to the company's restricted stock incentive plan, including the lifting of restrictions on certain shares and the repurchase and cancellation of others. The document includes voting results and references to related announcements on the stock exchange website. The content focuses on board decisions and management actions rather than financial results, audit opinions, or shareholder meeting materials. It is not a full annual or interim report, nor a call transcript or earnings release. The document is best classified as Board/Management Information (MANG) because it announces decisions made by the board of directors regarding stock incentive plans and share repurchases related to management and employee incentives.
2021-11-10 Chinese
金宇生物技术股份有限公司关于回购注销部分限制性股票（暨减少注册资本）通知债权人的公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement by a company regarding the repurchase and cancellation of restricted shares, which leads to a reduction in registered capital. It notifies creditors about their rights to claim debts or request guarantees within a specified period. The content focuses on the share repurchase and capital reduction process, creditor notification, and related procedural details. It is not a full financial report, earnings release, or management discussion. It is a formal announcement about a share repurchase and capital change event.
2021-11-10 Chinese
金宇生物技术股份有限公司独立董事关于第十届董事会第十四次会议相关事项的独立意见
Regulatory Filings
2021-11-10 Chinese
金宇生物技术股份有限公司关于2020年限制性股票激励计划首次授予第一个限售期解除限售条件成就的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company regarding the achievement of conditions for the first lock-up period release under a 2020 restricted stock incentive plan. It details the number of shares unlocked, the number of eligible participants, the decision-making process, legal opinions, and related board and supervisory committee approvals. The content focuses on stock incentive plan details, lock-up release conditions, and share repurchase related to the incentive plan. This is a corporate announcement about share-based compensation and stock unlocking, not a financial report, earnings release, or management discussion. It is not a proxy solicitation or voting result announcement either. The document fits best into the category of Regulatory Filings (RNS) as it is a regulatory announcement about stock incentive plan lock-up release and related corporate actions, without being a full report or financial statement.
2021-11-10 Chinese
金宇生物技术股份有限公司股份关于2020年限制性股票激励计划预留权益授予的进展公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from a company regarding the progress of granting reserved restricted stock under a 2020 restricted stock incentive plan. It details the number of shares granted, the approval by the board, and changes in share structure due to the stock grant. The document is relatively short (1105 characters) and focuses on a specific corporate action related to share issuance and stock incentives. It is not a full financial report, audit, or earnings release. It is not a proxy or voting result announcement. The content fits best with announcements about share issues or capital changes, specifically related to restricted stock grants and changes in share classification. Therefore, the document should be classified as a Share Issue/Capital Change (SHA) filing.
2021-11-08 Chinese
金宇生物技术股份有限公司2021年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2021 年第三季度报告' which translates to '2021 Third Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the third quarter of 2021. The document explicitly states it is a quarterly report and includes unaudited financial statements for the period ending September 30, 2021. The length of the document (over 14,000 characters) and the presence of substantive financial data confirm it is a full financial report rather than an announcement or summary. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). 9M 2021
2021-10-28 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.